{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.4","upperLimit":"33.9","value":"8.3"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"23.8","value":"0.0"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"25.9","value":"0.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants achieving either a Complete Response (CR) or partial Response (PR) based on the Investigator review. The responses were assessed by CT or MRI based on Response Evaluation Criteria In Solid Tumors Criteria (RECIST1.1). CR, disappearance of all target and non-target lesions; PR, at least a 30% decrease in the disease measurement, taking as reference the disease measurement done to confirm measurable disease at study enrollment, also no new lesion or progression of any non-target measurable lesion. Confirmation was based on the disease assessment at 1 cycle or at the next scheduled visit after the initial response. Only descriptive analysis performed.","dispersionType":"90% Confidence Interval","groups":[{"description":"Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\\^2/dose or as a powder in suspension at a dose of 225 mg/m\\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\\^2/dose was not tolerated (\\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.","id":"OG000","title":"Cohort 1: Rhabdomyosarcoma (RMS)"},{"description":"Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\\^2/dose or as a powder in suspension at a dose of 225 mg/m\\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\\^2/dose was not tolerated (\\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.","id":"OG001","title":"Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS)"},{"description":"Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\\^2/dose or as a powder in suspension at a dose of 225 mg/m\\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\\^2/dose was not tolerated (\\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.","id":"OG002","title":"Cohort 3: Ewing Sarcoma/pPNET (Ewing)"}],"paramType":"NUMBER","populationDescription":"mITT Set","reportingStatus":"POSTED","timeFrame":"From date of first dose of study treatment up to 55 months","title":"Percentage of Participants Achieving Objective Response Rate (ORR) in Subjects' With Tumors of Primary Interest (RMS, NRSTS or Ewing Sarcoma/pPNET)","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}